XGen Pharmaceuticals DJB
Kimberly Johnson has a strong background in quality assurance and compliance. Kimberly currently holds the position of Vice President QA at XGen Pharmaceuticals DJB, a role they have held since August 2020. Prior to this, they worked as a Consultant at CfPA - The Center for Professional Advancement starting in September 2019.
From September 2018 to September 2019, Kimberly served as the Site Head Quality Assurance at Cambrex. Before that, they worked as a Consultant at PathWise from March 2016 until their most recent job in 2018.
Kimberly also has an extensive work history at Pii (Pharmaceutics International, Inc.). Kimberly held various positions there, including VP QA Corporate Compliance from June 2014 to March 2016, Sr. Director of Quality Assurance Audits and Compliance from July 2009 to June 2014, and Director of Quality Assurance from January 2006 to July 2009.
Kimberly Johnson holds a Master's Degree in Quality Assurance & Regulatory Affairs from Temple University Graduate School. Kimberly also obtained a Bachelor's Degree in Chemistry from the State University of New York at Oswego. However, the specific start and end years for these degrees are not provided, so their exact timeline of education cannot be determined.
This person is not in any offices
XGen Pharmaceuticals DJB
Approaching the end of a 20 year career at a major pharmaceutical company, Dan Badia made a discovery. Where larger companies found obsolescence in small markets or low-profit yielding drugs, Dan saw reliable solutions proven to be effective and affordable alternatives for healthcare. With his wife, Shirley Harmening, Dan founded a company in 1973 on a bridge table in his bedroom. In just 14 years, this company would outgrow its birthplace and find a home in lower upstate New York. That growth would be sustained by introducing injectables into an established product line, mainly consisting of anti-infective, compounding powders. In 2003, that company would become X-GEN Pharmaceuticals, Inc. Affirming Dan’s original vision while embracing a dynamic industry, family-owned X-GEN Pharmaceuticals, Inc. remained a leader in generic, anti-infective pharmaceuticals. In this our 50th year in affiliation, we honor this heritage by carrying our founder’s initials in our new name, XGen Pharmaceuticals DJB. With reverence for the past and a passion for the future, we expect big results, driven by bold solutions and delivered by real people.